DAXOR CORP (DXR) Stock Price, Quote, News and Overview
NASDAQ:DXR - Nasdaq - US2394671034 - Common Stock - Currency: USD
DXR Quote, Performance and Key Statistics
NASDAQ:DXR (8/15/2025, 8:16:35 PM)
10.6
-0.01 (-0.09%)
The current stock price of DXR is 10.6 USD. In the past month the price increased by 13.37%. In the past year, price increased by 17.78%.
DXR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 26.89 | 229.22B | ||
| ISRG | INTUITIVE SURGICAL INC | 59.66 | 172.16B | ||
| BSX | BOSTON SCIENTIFIC CORP | 36.46 | 152.63B | ||
| SYK | STRYKER CORP | 29.72 | 145.95B | ||
| MDT | MEDTRONIC PLC | 16.91 | 119.18B | ||
| BDX | BECTON DICKINSON AND CO | 13.73 | 56.16B | ||
| IDXX | IDEXX LABORATORIES INC | 54.19 | 52.34B | ||
| EW | EDWARDS LIFESCIENCES CORP | 30.45 | 45.95B | ||
| RMD | RESMED INC | 29.83 | 41.77B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.75 | 33.61B | ||
| DXCM | DEXCOM INC | 47.62 | 31.74B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 16.35 | 26.45B |
Related stock screener links
About DXR
Company Profile
Daxor Corp is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in New York City, New York. Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. The company specializes in blood volume measurement technology focused on blood volume testing innovation. The company markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. The company has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.
Company Info
DAXOR CORP
Suite 7120, 350 Fifth Avenue
New York City NEW YORK 10118 US
CEO: Joseph Feldschuh
Employees: 0
Phone: 12122440555
DAXOR CORP / DXR FAQ
What is the stock price of DAXOR CORP today?
The current stock price of DXR is 10.6 USD. The price decreased by -0.09% in the last trading session.
What is the ticker symbol for DAXOR CORP stock?
The exchange symbol of DAXOR CORP is DXR and it is listed on the Nasdaq exchange.
On which exchange is DXR stock listed?
DXR stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for DAXOR CORP stock?
6 analysts have analysed DXR and the average price target is 25.5 USD. This implies a price increase of 140.57% is expected in the next year compared to the current price of 10.6. Check the DAXOR CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is DAXOR CORP worth?
DAXOR CORP (DXR) has a market capitalization of 52.58M USD. This makes DXR a Micro Cap stock.
How many employees does DAXOR CORP have?
DAXOR CORP (DXR) currently has 0 employees.
What are the support and resistance levels for DAXOR CORP (DXR) stock?
DAXOR CORP (DXR) has a support level at 9.8. Check the full technical report for a detailed analysis of DXR support and resistance levels.
Should I buy DAXOR CORP (DXR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of DXR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of DXR, evaluating the profitability, health, valuation and growth aspects
- DAXOR CORP (DXR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- DAXOR CORP (DXR) Sales and EPS estimates to see what analysts future expectations are.
- DAXOR CORP (DXR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- DAXOR CORP (DXR) Insider and Institutional Ownership to learn about the owners and their transactions.
- DAXOR CORP (DXR) Stock Chart to make your own analysis
- DAXOR CORP (DXR) Latest news and press-releases to stay up to date.
Does DAXOR CORP (DXR) stock pay dividends?
DXR does not pay a dividend.
What is the Price/Earnings (PE) ratio of DAXOR CORP (DXR)?
The PE ratio for DAXOR CORP (DXR) is 62.35. This is based on the reported non-GAAP earnings per share of 0.17 and the current share price of 10.6 USD. Check the full fundamental report for a full analysis of the valuation metrics for DXR.
What is the Short Interest ratio of DAXOR CORP (DXR) stock?
The outstanding short interest for DAXOR CORP (DXR) is 0.51% of its float. Check the ownership tab for more information on the DXR short interest.
DXR Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to DXR. When comparing the yearly performance of all stocks, DXR is one of the better performing stocks in the market, outperforming 86.26% of all stocks.
DXR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to DXR. DXR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
DXR Financial Highlights
Over the last trailing twelve months DXR reported a non-GAAP Earnings per Share(EPS) of 0.17. The EPS increased by 574.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 447.75% | ||
| ROA | 1.46% | ||
| ROE | 1.5% | ||
| Debt/Equity | 0.02 |
DXR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to DXR. The Buy consensus is the average rating of analysts ratings from 6 analysts.